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ABSTRACT
Background: Ten ASAS/EULAR recommendations for
the management of ankylosing spondylitis (AS) were
published in 2006.
Objectives: (a) To disseminate and (b) to evaluate
conceptual agreement with, and (c) application of, these
recommendations as well as (d) potential barriers to the
application.
Methods: A questionnaire was sent to rheumatologists
in 10 countries. It included (a) the text of the
recommendations; (b) rheumatologists’ demographic
variables; (c) two numerical rating scales from 1 to 10 for
each recommendation: conceptual agreement with, and
application of, the recommendation (10 indicates maximal
agreement and maximal application); and (d) a list of
potential barriers to the application of the recommenda-
tion. Statistical analysis included descriptive and multi-
variate analyses.
Results: 7206 questionnaires were sent out; 1507 (21%)
were returned. Of the 1507 answering rheumatologists,
62% were men, mean (SD) age 49 (9) years, and 34%
had an academic position. Conceptual agreement with the
recommendations was high (mean (SD) for all recom-
mendations 8.9 (0.9)). Self-reported application was also
high (8.2 (1.0)). The difference between agreement and
application varied across recommendations and countries.
The most pronounced discrepancies were reported for
use of anti-tumour necrosis factor drugs in a few
countries, with funding as the most commonly reported
barrier for application of this recommendation.
Conclusion: This large project has helped the dissemi-
nation of the ASAS/EULAR recommendations for the
management of AS and shows that conceptual agree-
ment with the recommendations is very high. The project
also highlights inequalities in access to healthcare for
European citizens with AS.
In 2006, recommendations for the management of
ankylosing spondylitis (AS) were published under
the umbrella of the ASsessment in AS international
working group (ASAS), and the European League
Against Rheumatism (EULAR).
1 These recommen-
dations concern all aspects of management of AS
(box 1). The Institutes of Medicine define clinical
practice guidelines or recommendations as
‘‘systematically developed statements to assist
practitioner and patient decision about approp-
riate health care for specific clinical circum-
stances’’. Clinical guidelines may induce small
improvements, both in processes and in the out-
comes of care.
2 However, if recommendations are
to have effect, it is necessary, after having
published them, to facilitate their dissemination.
3
Simple top-down dissemination of monodisciplin-
ary guidelines alone is not effective.
4–8 A more
powerful strategy to change behaviour is to involve
doctors directly.
9 Implementation experts indicate
that multistage involvement in the development of
a guideline can be a positive contributor to
effective implementation of guidelines.
10 11
Therefore, an ASAS-initiated project was per-
formed in 2006, involving practising rheumatolo-
gists in 10 countries.
The objectives of this study were (a)t o
disseminate and (b) to evaluate conceptual agree-
ment with, and (c) self-reported application as well
as (d) potential barriers to the application of, the
ASAS/EULAR recommendations among rheuma-
tologists from 10 different countries.
METHODS
This project was initiated by ASAS, supervised by
Maxime Dougados (France) and Tore K Kvien
(Norway) and financially supported by Wyeth
Europa pharmaceutical company.
A questionnaire was prepared which included
the text of the recommendations, demographic
variables (age, sex, academic position or not,
number of years of practice and mean number of
rheumatic patients and patients with AS seen a
month) and a numerical rating scale (NRS) from 1
to 10 for conceptual agreement and application of
each recommendation (10 indicated maximal
agreement and maximal application). The text
was: ‘‘Do you conceptually agree with this
recommendation?’’ and ‘‘Are you applying this
recommendation in your daily practice?’’. The
questionnaire also included a list of potential
barriers to the application of the recommendation
(the rheumatologist could tick as many barriers as
applicable). The barriers were different for each
recommendation and were selected by the authors
on the basis of clinical experience. Respondents
could also volunteer additional barriers.
Ten countries participated: Arabian Gulf,
Belgium, Czech Republic, France, Germany, Italy,
the Netherlands, Norway, Spain and the United
Kingdom (UK). For each country, a national
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sent it out to rheumatologists between March and September
2006. The list of rheumatologists who would receive the
questionnaire was freely chosen by the national investigator.
The rheumatologists were asked to complete and return the
questionnaire to the national investigator.
Statistical analysis was performed by LG on anonymous data
with knowledge of country; analysis was descriptive for
conceptual agreement and self-reported application.
Multivariate logistic regression analyses were also performed.
In the first, the dependent variable was conceptual agreement
per doctor, binarised at the mean conceptual agreement for that
recommendation. In the second analysis the dependent variable
was the individual difference between agreement and applica-
tion (ie, agreement minus application for a given doctor), also
binarised at the mean. The independent variables entered in
both analyses were country and the characteristics of the
rheumatologist. Statistical analyses were performed with SAS
version 9.0.
RESULTS
Response rate and participants
A total of 7206 questionnaires were sent out. The response rate
varied across countries from 49% (Italy) to 11% (Spain), but the
number of mailed questionnaires also varied widely between
countries (table 1). Thus, the total number of questionnaires
returned and analysed was 1507 (21% of all questionnaires), of
which 413 (27%) of all analysed questionnaires were from
France and 301 (20%) were from Germany (table 1).
Table 1 shows the characteristics of the rheumatologists. Of
respondents, 62% were men, mean (SD) age 49 (9) years, mean
(SD) years of practice 17 (9), and 34% reported having an
academic position. The mean (SD) number of patients seen a
month was 234 (172) and the mean (SD) number of patients
with AS seen a month was 15.6 (29.8).
Conceptual agreement
Conceptual agreement with the recommendations was eval-
uated separately for each recommendation, and was generally
high. Mean (SD) for all recommendations and all countries was
8.9 (0.9) (table 2), and more than 80% of all rheumatologists
had an agreement >7 for all recommendations combined
(table 2). Agreement was highest for recommendation 3
(‘‘optimal management of AS requires a combination of non-
pharmacological and pharmacological treatments’’) and recom-
mendation 1 (‘‘tailoring of treatment’’) (mean (SD) 9.5 (1.1)
and 9.3 (1.2), respectively). Agreement was lowest for
recommendation 6 (‘‘analgesics, such as paracetamol and
opioids, might be considered’’) with a mean (SD) value of 8.3
(2.0).
Agreement varied across countries; mean agreement with all
recommendations was highest in the Czech Republic (mean
(SD) 9.4 (0.5)) and in Norway (mean (SD) 9.2 (0.6)) and was
lowest in Belgium (mean (SD) 8.5 (1.4)).
Multivariate analyses were performed to explain agreement
with the recommendations. For all recommendations pooled,
the country of the investigator was not statistically associated
with agreement. Only female gender (odds ratio (OR)=1.33,
95% confidence interval (CI) 1.03 to 1.72, p=0.028) and
academic position (OR=1.31, 95% CI 1.02 to 1.70, p=0.032)
were predictive of higher agreement. However, this statistical
significance did not reflect clinical relevance. Mean (SD)
agreement scores were 8.93 (0.930) versus 8.84 (0.90) for
female versus male rheumatologists, and 8.95 (0.81) versus
8.80 (0.96) for academics versus non-academics, thus high for
all doctors.
Box 1: ASAS/EULAR recommendations for the
management of ankylosing spondylitis (AS)
1
1. Treatment of AS should be tailored according to current
manifestations of the disease (axial, peripheral, entheseal,
extra-articular symptoms and signs), level of current
symptoms, clinical findings and prognostic indicators:
disease activity/inflammation; pain; function, disability,
handicap; structural damage, hip involvement, spinal
deformities; general clinical status (age, sex, comorbidity,
concomitant drugs); wishes and expectations of the patient.
2. Disease monitoring of patients with AS should include a
patient history (eg, questionnaires), clinical measures,
laboratory tests and imaging, all according to the clinical
presentation, as well as the ASAS core set*. The frequency
of monitoring should be decided on an individual basis
depending on symptoms, severity and drug treatment.
3. Optimal management of AS requires a combination of non-
pharmacological and pharmacological treatments.
4. Non-pharmacological treatment of AS should include patient
education and regular exercise. Individual and group
physical therapy should be considered and patient
associations and self-help groups may be useful.
5. Non-steroidal anti-inflammatory drugs (NSAIDs) are
recommended as first-line drug treatment for patients with
AS who have pain and stiffness. In those with increased
gastrointestinal risk, non-selective NSAIDs plus a
gastroprotective agent, or a selective COX-2 inhibitor could
be used.
6. Analgesics, such as paracetamol and opioids, might be
considered for pain control in patients in whom NSAIDs are
insufficient, contraindicated and/or poorly tolerated.
7. Corticosteroid injections directed to the local site of
musculoskeletal inflammation may be considered. The use
of systemic corticosteroids for axial disease is not
supported by evidence.
8. There is no evidence for the efficacy of disease-modifying
antirheumatic drugs (DMARDs), including sulfasalazine and
methotrexate, for the treatment of axial disease.
Sulfasalazine may be considered in patients with peripheral
arthritis.
9. Anti-tumour necrosis factor (TNF) treatment should be given
to patients with persistently high disease activity despite
conventional treatments according to the ASAS
recommendations. There is no evidence to support the
obligatory use of DMARDs before, or concomitant with,
anti-TNF treatment in patients with axial disease.
10. Total hip arthroplasty should be considered in patients with
refractory pain or disability and radiographic evidence of
structural damage, independent of age. Spinal surgery—for
example, corrective osteotomy and stabilisation
procedures— may be of value in selected patients.
*The ASAS core set includes domains on axial, peripheral and
enthesopathological manifestations. One or more specific instru-
ments are recommended for each domain.
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Self-declared application of recommendations was also high, but
lower than conceptual agreement (mean (SD) 8.2 (1.0)) (table 2).
Application scores higher than 7 were reported by 81.7% of the
doctors. Self-reported application was highest for recommenda-
tion 5 (‘‘non-steroidal anti-inflammatory drugs (NSAIDs) are
recommended as first-line drug treatment’’) with mean (SD)
score 8.9 (1.5). Self-reported application was lowest for
recommendation 4 (‘‘non-pharmacological treatment of AS
should include patient education and regular exercise.
Individual and group physical therapy should be considered
and patient associations and self-help groups may be useful’’)
and recommendation 2 (‘‘disease monitoring of patients with
AS’’) with mean (SD) scores of 7.5 (2.1) and 7.7 (2.0),
respectively.
Application varied across countries; mean (SD) self-reported
application of all recommendations was highest in the Czech
Republic (8.5 (0.9)) and was lowest in the UK (7.8 (0.9)).
Difference between agreement and self-reported application
We calculated, for each recommendation, the difference for each
doctor between self-declared agreement and application—that
is, agreement minus application. This score could range from 0
(no difference between agreement and application) to 10 (total
agreement but no application). Theoretically, negative scores
could also be obtained (if application was higher than
agreement).
The differences between agreement and application varied
across recommendations and across countries (table 2). The
difference between agreement and application had mean values
above 1.0 for three recommendations. The highest values were
1.4 (1.8), for recommendation 4 (‘‘non-pharmacological treat-
ment of AS’’), 1.1 (1.6), for recommendation 2 (‘‘disease
monitoring of patients with AS’’) and 1.0 (2.0), for recommen-
dation 9 (‘‘anti-tumour necrosis factor (TNF)’’). The lowest
values were observed for recommendations 5 and 8 (mean 0.3
(0.9) and 0.3 (1.2), respectively). There were no negative scores.
The largest overall country differences between agreement
and application were recorded in Italy (1.0 (0.8)) and the UK
(1.0 (0.9)). For recommendation 4, mean difference scores were
.1 for all countries except the Netherlands and Norway, but
were .2 only for Italy. For recommendation 2, mean difference
scores were .1 for all countries except France and Germany,
but were .2 only for the UK. For recommendation 9 (‘‘anti-
TNF’’), mean difference scores were ,1 for all countries except
UK (2.8 (3.0)), Czech Republic (2.7 (2.9)) and the Arabian Gulf
(1.6 (2.3)).
Multivariate analyses were performed to explain this differ-
ence between agreement and application. Country was the only
independent variable which was significantly associated with
the difference between agreement and application (p,0.001)
(data not shown).
Barriers to application of recommendations
Table 3 shows items presented as potential barriers and ticked
by more than 25% of rheumatologists. A high proportion of
doctors felt there was no specific barrier to the application of
recommendations 1, 5, 6, 7, 8 and 10 (more than 40% ticked the
item ‘‘there is no specific barrier’’). The potential presence of
barriers for application was most frequently reported for
recommendation 4 (no barrier, 19.7%), 2, 3 and 9 (no barrier,
30.3%, 32.0% and 34.5%, respectively).
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mendation’’ was included in the questionnaire for all recom-
mendations but was infrequently ticked (0.2% to 6% for all
recommendations).
For recommendations 1 and 2, the most frequent barrier
(26.1% and 42.4% of doctors, respectively) was ‘‘lack of time’’.
More than 70% of doctors in Spain and the UK reported this
barrier for recommendation 2. For recommendation 4, the most
frequent barrier (47.1% of doctors) was ‘‘lack of patient
compliance with recommendations’’. The second most frequent
barrier (32.9%) was ‘‘lack of facilities for education’’, particu-
larly in Spain (50.4%). The most frequent barrier (37.8%) for
recommendation 5 was ‘‘concerns about the safety of long-term
use of NSAIDs/COX-2 inhibitors’’, but 41.7% reported no
specific barrier. For recommendation 6, 47.4% of doctors
reported no specific barrier; but 29.9% reported that ‘‘fear of
addiction/tolerance to opioids with long-term use’’ was a
barrier. The most frequent barrier (32.1%) for recommendation
7 was ‘‘patient concerns about use of corticosteroid injections’’
but 47.0% of doctors reported no specific barrier for the
application of this recommendation.
For recommendation 9 regarding use of anti-TNF drugs in
patients with AS, the most frequent barriers were ‘‘insufficient
funding’’ (25.9%), and ‘‘administrative burden associated with
anti-TNF treatment’’ (25.6%). Major differences across coun-
tries were observed for this item. Barriers related to funding
were frequently reported in the Czech Republic (78.1%) and the
UK (65.8%), whereas Italian doctors frequently reported barriers
related to administrative burden (43.0%).
DISCUSSION
This large project has helped the dissemination of the ASAS/
EULAR recommendations for the management of AS: 7206
rheumatologists received the questionnaire and thus also the
text of the recommendations, and 1507 answered and are
assumed to have at least read the recommendations. The results
from the survey showed that conceptual agreement with the
recommendations was very high (mean 8.9), and self-declared
application was also high, though somewhat lower (mean 8.2).
Raising implementation of recommendations is not an easy
task. Implementation experts indicate that the effect of issued
recommendations on clinical practice is improved if practising
clinicians actively contribute to the development of the
recommendations.
12 If this involvement is not feasible, creation
of a sense of ‘‘ownership’’ through a process of dissemination is
essential for successful implementation of recommendations in
clinical practice.
10 12 We have paid specific attention to these
aspects, first, by involving worldwide representation of rheu-
matologists in the elaboration
1, and second, by focusing
specifically on the doctors’ acceptance of the recommendations
by including them in the validation procedure, and giving them
the opportunity to express their agreement and practical
applicability of each recommendation.
Agreements with the 10 recommendations were generally
high. The ASAS group is possibly considered as an opinion
leader to such extent that the rheumatologists did not feel
justified, or diplomatic, to disagree with recommendations that
were prepared by experts they trusted. Another factor that
might have had an impact on the validity of the results is the
method of data collection. Some authors have recommended
feedback meetings rather than questionnaires as an effective
method to create involvement among doctors during a
validation procedure.
9 However, meetings are time consuming
and costly and their impact may be only moderate.
9
Furthermore, some doctors might have had comments that
were not expressed since they considered that their input would
not have any impact in the final recommendations. Another
potential explanation is related to selection of respondents by
their agreement. This is a possible bias which needs to be
discussed because the response rate (21%) is very low, and the
percentage of academic doctors is high (34%). However, it
should be noted that these response rates in the context of an
implementation project were reasonable. Response rates varied
across countries, and were higher in countries where fewer
rheumatologists were solicited, presumably because in these
countries a selection was operated before sending the ques-
tionnaires—that is, these doctors were all treating patients with
AS and wanted to answer. The reason for this low response
rate, in particular, in certain countries is probably a suboptimal
selection of the rheumatologists receiving the questionnaires.
The list of recipients was freely determined by the principal
investigator for each country, and in some countries a national
society of rheumatology members’ list was used. This selection
method may be insufficiently directed towards interested
rheumatologists, involved with patients with AS, which may
explain the low response rate. It also may explain why some of
the responding rheumatologists reported having a small number
of patients with AS.
The application of recommendations for management is
generally important for the quality of patient care. Self-reported
application of these recommendations was generally high across
Europe. The implementation of guidelines and recommenda-
tions remains a challenge world wide, as barriers exist at several
levels. These barriers may be generic, such as national
limitations to prescriptions of expensive drugs or a general lack
of adequate resources and/or poor infrastructure. Other
potential barriers include the organisational level, the healthcare
provider and patient factors. Some barriers are, however,
potentially correctable, and the goal of the implementation of
the recommendations for AS management is to translate
evidence-based AS management recommendations into ‘‘real-
life’’ practice which ultimately will lead to improved health
status for patients with AS. It should be noted, however, that
this study did not allow us to truly assess application of the
ASAS-EULAR recommendations, but only the self-reported
application. The possibility of a gap between self-declared
application of recommendations, and their true application
cannot be excluded.
The differences between agreement and application are of
particular interest, since these differences reflect areas in which
the doctors agreed with the recommendations, but reported
they did not implement them. This section of the results also
disclosed differences between countries, which is important
since equality in access to healthcare should be a general goal in
Europe The difference between agreement and application was
high for recommendations 2, 4 and 9 and the overall country
differences were highest in Italy and the UK. Recommendation
2 was deemed difficult to apply because of lack of time and this
concern was especially reported by doctors in the UK. The
country difference between agreement and application was
pronounced for recommendation 9 (‘‘anti-TNF’’), and the
largest discrepancy between agreement and the possibility of
applying the recommendations was reported by doctors from
the UK and the Czech Republic. The barriers cited by doctors
refer to funding and administrative burden of anti-TNF. Thus,
according to our results, there are inequalities in access to
treatment and healthcare in Europe. The unfortunate situation
for patients with AS in UK is not surprising since previous
Extended report
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patients with rheumatoid arthritis is more limited in the UK than
in, forexample, the NetherlandsandtheScandinaviancountries.
13
In conclusion, this project supported the dissemination of
evidence-based recommendations for AS. However, the project
also disclosed intercountry differences for conceptual agreement
with the recommendations and implementation of the recom-
mendations in clinical practice. The results show that inequal-
ities exist in the provision of healthcare for patients with AS in
Europe, even between countries who are members of the
European Union.
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